Interferon-gamma Inducible Protein 10 - biomarkerfor treatment outcome in chronic hepatitis C

摘要

The predictive value of two easy-to-determine serum biomarkers: IP-10 (Interferon-gammainducible protein-10 kD) and sCD26 (soluble CD26) on the virological response of interferon-basedtherapy was assessed in 119 patients with chronic hepatitis C. Patients who obtained sustainedvirological response (SVR) had significantly decreased baseline IP-10 concentrations as compared tonon-responders (mean IP-10 = 338 ± 200 pg/mL vs. 472.7 ± 254 g/mL; p=0.003). Correlation of thisinexpensive serological marker with IL2B genotype and baseline HCV viral load can be used in theselection of patients who might benefit from interferon-based therapies, which are currently availablein developing economies. On the contrary, there was no correlation between the baseline concentrationof sCD26 and the outcome of treatment. IP-10 might be a suitable biomarker to predict virologicalsuccess after pegylated interferon alpha and ribavirin treatment.